Tue, Sep-01-20, 09:02
|
|
Senior Member
Posts: 4,324
|
|
Plan: vLC/GF,CF,SF
Stats: 197/136/150
BF:
Progress: 130%
Location: Alberta
|
|
Conflict of Interest listed on the paper: One of the authors, Pam Taub: Consultant to Sanofi/Regeneron, Novo-Nordisk, Boehringer-Ingelheim, Janssen, Amgen, Amarin, Pfizer, Esperion Therapeutics. Shareholder of Epirium Bio; all other authors report no conflicts of interest.
|